List of Excipients in Branded Drug XROMI

« Back to Dashboard

Xromi Excipient Strategy and Commercial Opportunities in Pediatric Sickle Cell Disease

Last updated: September 24, 2026

Xromi is a 100 mg/mL oral solution of hydroxycarbamide, also known as hydroxyurea, developed for sickle cell disease, including pediatric use. Its commercial differentiation depends less on the active ingredient, which is an established generic molecule, and more on liquid dosing, palatability, dose flexibility, caregiver handling, and access outside specialist centers. The current excipient system is relatively simple: sodium benzoate, citric acid monohydrate, sodium citrate, purified water, and strawberry flavor.[1]

The strongest lifecycle opportunities are an improved pediatric liquid, a preservative-free presentation, better taste masking, unit-dose packaging, and geographic expansion. Biosimilar risk does not apply because hydroxycarbamide is a small-molecule drug. Generic and formulation competition remain the main threats.

What is Xromi and who markets it?

Xromi contains hydroxycarbamide at a concentration of 100 mg/mL. The product is intended to support oral treatment of sickle cell disease when individualized dosing and administration to children are important.[1]

Attribute	Xromi
Active ingredient	Hydroxycarbamide
Strength	100 mg/mL oral solution
Primary therapeutic area	Sickle cell disease
Dosage form	Ready-to-use oral liquid
Key patient group	Children and patients unable to swallow solid dosage forms
Preservative	Sodium benzoate
Flavor	Strawberry flavor
Regulatory positioning	UK-authorized medicinal product
Main commercial alternatives	Hydroxycarbamide capsules, tablets, compounded liquids

Xromi’s concentration allows dose adjustment in milligram increments without tablet splitting. At 100 mg/mL, a 500 mg dose requires 5 mL, while a 1,000 mg dose requires 10 mL. This supports titration but creates a practical need for accurate oral syringes and caregiver training.

What excipients are used in Xromi?

The Xromi product information identifies sodium benzoate, citric acid monohydrate, sodium citrate, purified water, and strawberry flavor as excipients.[1]

Excipient	Functional role	Commercial and regulatory relevance
Sodium benzoate	Antimicrobial preservative	Supports multidose shelf life; creates pediatric excipient and labeling considerations
Citric acid monohydrate	Acidulant and pH adjuster	Contributes to chemical stability and taste profile
Sodium citrate	Buffering agent	Controls pH and supports stability
Purified water	Vehicle	Defines the aqueous liquid system
Strawberry flavor	Palatability agent	Supports pediatric acceptability but may require flavor and allergen assessment

The formulation strategy is conventional for a multidose aqueous oral solution. The central technical tradeoff is between microbiological protection, chemical stability, taste, and excipient burden.

How does sodium benzoate affect Xromi’s commercial position?

Sodium benzoate permits a multidose liquid presentation without relying on refrigeration or extemporaneous compounding. That improves distribution and reduces pharmacy preparation requirements.

Its disadvantages are strategic rather than necessarily clinical. Pediatric medicines receive close scrutiny for preservative exposure, excipient labeling, and cumulative intake across products. A competing preservative-free formulation could be positioned for neonatal, infant, or institutionally sensitive use, subject to adequate container-closure protection and microbiological validation.

A preservative-free product would need to address:

• In-use contamination over the intended administration period
• Low-dose withdrawal accuracy
• Container-closure integrity
• Compatibility with oral syringes
• Stability after opening
• Manufacturing and filling controls
• Cost of sterile or highly controlled production, if required by the chosen design

A preservative-free formulation would not automatically be superior. The commercial value would depend on whether clinicians and procurement bodies consider reduced preservative exposure worth a higher price.

What is the role of the citrate buffer?

Citric acid and sodium citrate provide a buffered aqueous environment. The buffer can support hydroxycarbamide stability, but it can also influence sourness, aftertaste, and flavor performance.

Potential reformulation work should evaluate pH as a multidimensional variable rather than a stability-only parameter. A pH adjustment can affect:

• Hydroxycarbamide degradation
• Flavor intensity
• Sweetness perception
• Mouthfeel
• Container compatibility
• Preservative efficacy
• Patient acceptance

Any reformulation would require comparative stability, preservative-effectiveness, microbial limits, extractables and leachables, and bioequivalence or bridging analysis where applicable.

What formulation patents could protect Xromi or a successor product?

The active ingredient is old and widely available. Commercial protection therefore depends on formulation, use, device, manufacturing, and regulatory exclusivity rather than composition-of-matter protection for hydroxycarbamide.

Potential claim areas include:

1. A stable hydroxycarbamide oral solution at a defined concentration and pH range.
2. A specific preservative system with validated multidose stability.
3. A taste-masked formulation using a defined flavor, sweetener, or coating technology.
4. A low-excipient or preservative-free aqueous formulation.
5. A ready-to-administer unit-dose container.
6. A dosing system that reduces occupational exposure during handling.
7. A manufacturing process that limits degradation or microbial contamination.
8. A method of treating pediatric sickle cell disease using weight-based liquid dosing.

Patent strength would vary by claim type. Broad claims to hydroxycarbamide in an oral liquid are vulnerable because oral liquids and hydroxycarbamide formulations are likely to have substantial prior art. Narrow claims tied to a demonstrated stability advantage, preservative-free multidose performance, or a specific container-device combination would be more defensible if supported by comparative data.

When does Xromi lose exclusivity?

Xromi’s exclusivity cannot be assessed from the active ingredient alone. Hydroxycarbamide has long been available in other dosage forms, including capsules and tablets. The relevant protection is product-specific and may include patents, regulatory exclusivity, trademarks, know-how, and market access arrangements.

Exclusivity layer	Relevance to Xromi
Active-ingredient patent	Not a meaningful barrier because hydroxycarbamide is established
Formulation patent	Potentially relevant if claims cover the liquid composition or stability profile
Method-of-use patent	Potentially relevant for pediatric dosing or a defined sickle cell regimen
Trademark	Protects the Xromi brand but not the underlying formulation
Regulatory exclusivity	Depends on the jurisdiction and authorization pathway
Manufacturing know-how	May delay direct substitution even where patents are weak
Device and packaging rights	Can protect administration and handling systems

A precise expiration date for any Xromi-specific patent requires a verified patent-family review across the UK, Europe, the United States, and other target markets. The cited product information does not establish a definitive Xromi patent expiry date.[1]

What is the Orange Book status of Xromi?

Xromi does not have an FDA Orange Book listing unless and until it receives an FDA-approved application. The Orange Book records approved drug products and relevant patent and exclusivity information for FDA-approved products.[2]

This creates a material U.S. development opportunity. A U.S. sponsor could consider:

• A full 505(b)(1) application
• A 505(b)(2) application relying in part on existing hydroxyurea data
• An abbreviated application if a reference product and regulatory pathway support it
• A pediatric liquid development program linked to an established hydroxyurea reference product

The appropriate pathway would depend on formulation differences, bioavailability, clinical bridging requirements, and FDA acceptance of the reference framework. A European product cannot be assumed to qualify automatically for a U.S. abbreviated pathway.

What generic entry risks exist for Xromi?

The principal risk is substitution by lower-cost hydroxycarbamide products rather than by biosimilars.

Immediate-release solid dosage forms

Capsules and tablets are likely to remain the lowest-cost competitors. Their limitations include swallowing difficulty, dose inflexibility, tablet manipulation, and challenges in young children.

Compounded oral liquids

Compounding pharmacies can produce hydroxycarbamide liquids from capsules or powder. These products may compete on price, particularly where Xromi is not reimbursed or hospital formularies favor local preparation. Their disadvantages include variable availability, shelf-life constraints, flavor variability, and pharmacy workload.

Other commercial liquids

A rival ready-to-use liquid with a different preservative system, flavor, or concentration could compete directly. Concentrations above or below 100 mg/mL could target different dosing volumes, but a higher concentration may increase measurement risk in children.

Regulatory generic products

A generic equivalent could erode price if it demonstrates pharmaceutical equivalence and satisfies local regulatory requirements. Formulation patents, device rights, or regulatory exclusivity could delay entry but would not permanently protect the brand if the claims are narrow or invalidated.

How does Xromi compare with hydroxycarbamide capsules and tablets?

Factor	Xromi liquid	Capsules or tablets
Pediatric dosing	Strong flexibility	Limited unless dosage forms can be manipulated
Swallowing	Suitable for patients unable to swallow solids	Less suitable for young children
Dose precision	Dependent on syringe and technique	Dependent on available strengths
Stability after opening	Multidose in-use issue	Generally simpler solid-state storage
Palatability	Requires flavor acceptance	Taste may be less relevant if swallowed intact
Cost of goods	Higher due to liquid filling and packaging	Usually lower
Compounding burden	Low	May require pharmacy manipulation for some children
Handling risk	Liquid measurement and cytotoxic handling controls	Capsule or tablet handling also requires precautions

Xromi’s value proposition is strongest where the health system prioritizes pediatric adherence, accurate titration, and reduction of extemporaneous compounding.

What commercial opportunities exist for Xromi?

Preservative-free pediatric formulation

A preservative-free version could target hospitals, pediatric specialists, and caregivers seeking to reduce exposure to sodium benzoate. The product would require a validated microbiological and packaging strategy.

Improved taste masking

Hydroxycarbamide liquids can face adherence problems if the flavor is unacceptable. A dual-flavor platform, sweetener optimization, or taste-masking technology could support a differentiated product. The commercial claim should be based on controlled acceptability data rather than flavor selection alone.

Higher-concentration presentation

A higher concentration could reduce administration volume for older children and adults. It would also increase the consequences of measurement errors. Any such product should use a dedicated oral syringe with dose markings designed for the concentration.

Unit-dose packaging

Unit-dose sachets, stick packs, or oral syringes could reduce contamination and dosing errors. They would be more expensive than a bottle but may fit hospital, travel, and school-administration settings.

Integrated dosing device

A proprietary bottle-and-syringe system could improve dose accuracy and create device-related differentiation. The device should prevent connection errors, minimize residual volume, and accommodate low-volume pediatric doses.

Emerging-market access

Many sickle cell disease markets have limited access to pediatric hydroxyurea formulations. A lower-cost version using the current excipient architecture could address these markets, provided the sponsor can manage climate-zone stability, packaging robustness, supply reliability, and local registration requirements.

What manufacturing and intellectual-property barriers matter?

The manufacturing process is not intrinsically complex compared with sterile injectables, but aqueous cytotoxic products require disciplined controls. Key barriers include:

• Uniform hydroxycarbamide content throughout the batch
• Control of degradation products
• Preservative effectiveness
• Microbial limits
• Accurate liquid filling
• Container-closure compatibility
• Occupational exposure controls
• Cleaning validation
• Stability across intended climate zones
• In-use stability after repeated opening

Know-how may be more commercially important than patents. A supplier with validated flavor performance, stable preservative control, robust filling equipment, and reliable pediatric packaging can maintain an advantage even when competitors can legally make the same active ingredient.

What is the litigation and settlement outlook?

No specific Xromi Paragraph IV litigation or settlement can be established from the cited product and FDA sources. Because Xromi is not an FDA-approved Orange Book product, a conventional U.S. Orange Book Paragraph IV framework does not currently define its competitive position.[2]

The likely disputes would instead concern:

• Validity of liquid-formulation claims
• Infringement by a competing oral solution
• Ownership of formulation development data
• Trademark rights
• Distribution or licensing rights
• Regulatory reliance and data use
• Device and packaging patents

For a U.S. launch, the sponsor should expect formulation patent review to be more important than active-ingredient patent review.

How strong is the Xromi patent estate?

The apparent estate is strategically moderate rather than structurally strong. The product has a meaningful clinical and usability distinction over solid dosage forms, but hydroxycarbamide itself is not a new molecule. A durable estate would need layered protection covering formulation, device, manufacturing, and pediatric use.

Protection type	Expected strategic value
Broad hydroxycarbamide composition claim	Low
Narrow liquid formulation claim	Moderate
Stability-based formulation claim	Moderate to high if supported by comparative data
Taste-masking claim	Moderate
Preservative-free multidose claim	Moderate to high if technically demonstrated
Dosing-device claim	Moderate
Pediatric method-of-use claim	Variable
Manufacturing know-how	Moderate and difficult to quantify

Key Takeaways

• Xromi is a 100 mg/mL hydroxycarbamide oral solution for sickle cell disease, with particular value in pediatric dosing.
• Its disclosed excipients are sodium benzoate, citric acid monohydrate, sodium citrate, purified water, and strawberry flavor.[1]
• The strongest commercial differentiators are liquid dosing, dose flexibility, palatability, and reduced reliance on extemporaneous compounding.
• The principal competitive threats are capsules, tablets, compounded liquids, and future ready-to-use generic solutions.
• Biosimilar competition is irrelevant because hydroxycarbamide is a small molecule.
• A preservative-free formulation, improved taste masking, unit-dose packaging, or integrated dosing device could support lifecycle expansion.
• Xromi has no FDA Orange Book status unless and until a U.S. application is approved.[2]
• Patent value is most likely to reside in formulation, device, manufacturing, and pediatric-use claims rather than in hydroxycarbamide itself.
• A definitive patent-expiry analysis requires jurisdiction-specific review of the relevant patent families and regulatory records.

FAQs

Is Xromi a generic version of hydroxyurea?

Xromi contains hydroxycarbamide, the same active ingredient commonly called hydroxyurea in the United States. Its differentiation is the ready-to-use 100 mg/mL oral liquid rather than a new active molecule.

Can Xromi be reformulated without sodium benzoate?

Yes, a successor product could use a preservative-free design, but it would need validated microbiological protection, container-closure performance, in-use stability, and regulatory support.

Is Xromi suitable for infants?

The product is positioned for pediatric sickle cell disease, but age-specific use depends on the approved product information, prescriber judgment, dosing requirements, and local regulatory labeling.[1]

What is the main commercial advantage of a 100 mg/mL concentration?

The concentration permits flexible weight-based dosing and avoids tablet splitting. It also increases the importance of accurate syringe measurement and caregiver instruction.

Could a competing hydroxycarbamide liquid receive patent protection?

Yes. Protection could potentially cover a particular concentration, pH range, preservative system, taste-masking system, container, dosing device, manufacturing process, or validated stability profile. Broad claims would face greater prior-art exposure than narrowly defined technical claims.

References

1. Nova Laboratories Limited. (n.d.). Xromi 100 mg/mL oral solution: Summary of product characteristics. Electronic Medicines Compendium.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.